Roche Pharma R&D (pRED)

Our scientists are amongst the best in the industry, discovering and translating cutting-edge science in the pursuit of delivering life-changing benefits to patients.

We continue to be driven by our long-term aim to deliver these medical advances that provide greater benefits to patients, and at the same time, reduce the healthcare burden on society.

pRED's research spans across 7 disease areas:

andandand

See all stories

pRED scientists pursue excellence. Patients are waiting, so by pushing boundaries pRED scientists make breakthroughs every day. Find out some examples of areas where pRED is leading the field.

Advancing Novel Classes of Antibiotics

Roche’s commitment to creating and developing researching and developing new medicines to tackle drug resistance

Roche’s lifesaving legacy in antibiotic innovation

Finding new ways to kill bacteria is crucial against antimicrobial resistance. For Roche, it's been a 45-year legacy of innovative antibiotics and saving lives.

Doubling our vision

By combining a unique medical device with new medicines, Roche is turning breakthrough discoveries into groundbreaking inventions for patients with retinal disease

Defining hallmarks of stem cells

A new review from Roche scientists describe stem cells’ unique and shared features, laying the foundation of what is known about them and mapping new approaches in drug discovery

New era of antibiotics potentially in sight after more than 50 years

By finding a new class of antibiotics, Roche’s scientists could contribute to reducing the globally growing number of deaths related to hospital-acquired bacterial infections

The RNA Hub - An integrated multidisciplinary research community

Roche is shaking up the drug development process for new RNA-based medicines

The Best of Both Worlds

Roche is shaking up the drug development process for new RNA-based medicines

Crossing Barriers

Story descriptionExploring Roche’s Brainshuttle™ technology to open new treatment avenues

A New Vision

The Roche RNA Hub takes a fresh look at dry eye

Fighting inflammation in the eye

How a potential new molecule for retinal diseases could help close a gap of unmet medical need

An innovative hub for innovative medicines

Roche is shaking up the drug development process for new RNA-based medicines

From idea, to molecule, to medicine

The step-by-step evolution of a potential new approach to treating cancer.

Modeling the future

Roche launches the Institute of Human Biology to pioneer new approaches for drug discovery and development, leveraging human model systems such as organoids

Looking beyond the horizon to change the trajectory for vision loss

With millions of people worldwide living with retinal conditions, scientists at Roche have the ultimate goal to hopefully prevent, and even reverse, vision loss.

Meet the antibody engineers

How teams across Roche are tweaking versatile immune tools to develop new treatments

Harnessing Immune Power Against Tumours

How Roche follows the science to continue improving on bold new therapeutic strategies.

Pushing the boundaries of science: Following the Fibroblasts

How describing the structural cells of tissues sheds new light on autoimmune disease

Future cures are in our genes

The next generation of pioneering medicines, led by gene therapy, is blazing a path towards truly personalised global healthcare, strengthened by partnering.

Joining forces in neuroscience

Neurological disorders pose some of the greatest challenges and areas of unmet medical need. We are joining forces with others who are studying these challenges.

Reaching new antibody heights

Hear reflections from Roche pRED scientists on the science and innovation behind the pioneering advances in antibody technology for novel antibody therapeutics.

Introducing cancer immunotherapy

In recent years progress has been made in developing cancer immunotherapies that target specific aspects of an individual’s tumour.

Roche pRED publications

Roche is an innovation company pioneering the future of healthcare, science and R&D.

scientists are active members of the scientific community and publish in numerous peer-reviewed journals in the areas of Clinical Development, Pharmaceutical Sciences, Therapeutic Modalities and Translational Bioengineering; and

andandand

See all publications

Revolutionary discoveries in science are truly enabled when we have open minds and ears to share and collaborate.

Hans Clevers

Head of pRED, Roche

Meet the pRED scientists

See all stories

At pRED, it’s not the easy questions that excite us, it’s the biggest challenges in healthcare. That’s why we’ve set ourselves big goals to discover treatments that provide greater benefits for patients at a lower cost to society. This means having the expertise, resources and latest technologies at our fingertips, within an organisation that nurtures innovation built on curiosity and responsibility.

Innovation

Roche R&D locations

We have research and development sites all around the world.

Institute of Human Biology

The Institute of Human Biology (IHB) is dedicated to research on human biology and human model systems such as organoids. Roche Pharmaceutical Research and Early Development (pRED) established the IHB to take maximum advantage of the scientific and research expertise in both academia and the pharmaceutical industry, it will bring them closer together using human model systems to better predict a drug’s validity, and so translate pioneering science into breakthroughs for patients.

Innovation

Roche Accelerator

As Roche’s first in-house accelerator globally, Roche Accelerator aims to serve as an external innovation hub, to catalyze next-generation R&D and contribute to the innovation ecosystem.

RNA Hub

An integrated multidisciplinary RNA research community with focus on oligonucleotides And access to all of Roche’s research capabilities

Joint postdoctoral programme with ETH Zurich

To advance the development and application of bioengineering in translational medicine, the ETH Zurich Department of Biosystems Science and Engineering and Roche Pharma Research and Early Development launched the Bio-​Engineering Systems for Therapeutics (BEST) postdoc programme in Basel.

More from the Roche Group

Get to know our structure

Discover more

Careers